Literature DB >> 33367801

Severe Acute Respiratory Syndrome Coronavirus 2 Placental Infection and Inflammation Leading to Fetal Distress and Neonatal Multi-Organ Failure in an Asymptomatic Woman.

Sam Schoenmakers1, Pauline Snijder2, Robert M Verdijk3, Thijs Kuiken4, Sylvia S M Kamphuis5, Laurens P Koopman6, Thomas B Krasemann6, Melek Rousian1, Michelle Broekhuizen2,7, Eric A P Steegers1, Marion P G Koopmans4, Pieter L A Fraaij4,5, Irwin K M Reiss2.   

Abstract

BACKGROUND: In general, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy is not considered to be an increased risk for severe maternal outcomes but has been associated with an increased risk for fetal distress. Maternal-fetal transmission of SARS-CoV-2 was initially deemed uncertain; however, recently a few cases of vertical transmission have been reported. The intrauterine mechanisms, besides direct vertical transmission, leading to the perinatal adverse outcomes are not well understood.
METHODS: Multiple maternal, placental, and neonatal swabs were collected for the detection of SARS-CoV-2 using real-time quantitative polymerase chain reaction (RT-qPCR). Serology of immunoglobulins against SARS-CoV-2 was tested in maternal, umbilical cord, and neonatal blood. Placental examination included immunohistochemical investigation against SARS-CoV-2 antigen expression, with SARS-CoV-2 ribonucleic acid (RNA) in situ hybridization and transmission electron microscopy.
RESULTS: RT-qPCRs of the oropharynx, maternal blood, vagina, placenta, and urine were all positive over a period of 6 days, while breast milk, feces, and all neonatal samples tested negative. Placental findings showed the presence of SARS-CoV-2 particles with generalized inflammation characterized by histiocytic intervillositis with diffuse perivillous fibrin depositions with damage to the syncytiotrophoblasts.
CONCLUSIONS: Placental infection by SARS-CoV-2 leads to fibrin depositions hampering fetal-maternal gas exchange with resulting fetal distress necessitating a premature emergency cesarean section. Postpartum, the neonate showed a fetal or pediatric inflammatory multisystem-like syndrome with coronary artery ectasia temporarily associated with SARS-CoV-2 for which admittance and care on the neonatal intensive care unit (NICU) were required, despite being negative for SARS-CoV-2. This highlights the need for awareness of adverse fetal and neonatal outcomes during the current coronavirus disease 2019 pandemic, especially considering that the majority of pregnant women appear asymptomatic.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society.

Entities:  

Keywords:  Kawasaki-like syndrome; SARS-CoV-2; fetal distress; inflammation; placenta

Year:  2021        PMID: 33367801      PMCID: PMC7798999          DOI: 10.1093/jpids/piaa153

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


In general, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during pregnancy is not considered to be an increased risk for severe maternal outcomes but has been associated with an increased risk for fetal distress [1]. Localization of SARS-CoV-2 particles in placental tissue has been visualized [2, 3], and recently, a few cases of vertical transmission of SARS-CoV-2 have been reported [4-8]. Besides related to direct in utero infection with SARS-CoV-2, the mechanisms leading to the adverse perinatal outcomes are not well understood. We report an intra-placental SARS-CoV-2 infection at 31 + 4 weeks’ gestational age diagnosed by multiple methods, including immunohistochemistry, in situ hybridization, and transmission electron microscopy. Inflammation was characterized by histiocytic intervillositis with specific diffuse perivillous fibrin depositions and intervillous inflammatory infiltrates. Placental infection most likely resulted in fetal distress and related fetal cardiotocography abnormalities necessitating a premature emergency cesarean section. The neonate tested negative for SARS-CoV-2 but displayed severe multi-organ inflammatory symptoms including coronary artery ectasia for which admittance and care on the neonatal intensive care unit (NICU) were required.

RESULTS

Maternal

A 30-year-old obese primigravid woman with gestational diabetes was referred to our tertiary center at 31 + 4 weeks’ gestation due to lack of fetal movements during the last 2 days. She reported general malaise, myalgia, and fever 5 days earlier, which resolved within 3 days. At presentation to our perinatal center, she had no coronavirus disease 2019 (COVID-19)-related symptoms but mentioned that she shared a household with a COVID-19-positive person. Fetal cardiotocography showed signs of severe fetal distress, including loss of beat-to-beat variability and repetitive decelerations, for which an emergency cesarean section was performed. Because of her medical history resembling COVID-19-related symptoms, samples for SARS-CoV-2 diagnostics (polymerase chain reaction [PCR] and pathological analysis) were collected (see Table 1, Figure 1). Real-time quantitative PCR (RT-qPCR) was performed for the detection of SARS-CoV-2 using our in-house assay [9] or the Cobas SARS-CoV-2 test on the Cobas 6800 system (Roche Diagnostics) depending on the availability of platforms. Cycle threshold values were converted to log10 ribonucleic acid (RNA) copies/mL by using calibration curves based on quantified E-gene in vitro transcripts as previously described [9]. All collected PCR samples during delivery, including placental tissue slices, tested positive for SARS-CoV-2, except for the umbilical cord blood, feces, and breastmilk. Over a period of 11 days, maternal PCR sampling was repeated (Table 1), which all remained positive for SARS-CoV-2, except for breastmilk and feces. Results for repeated neonatal PCR sampling are described in the “Neonatal Outcome” section later. SARS-CoV-2 serology was performed using the commercially available Beijing Wantai Biological Pharmacy assay. At 1 day after delivery, maternal serology for SARS-CoV-2 was positive. Additional maternal blood tests showed a slightly elevated C-reactive protein (CRP) (41 mg/L) and IL-6 (11 pg/mL) levels, a positive interferon type 1 (IFN-1) signature, and normal levels of ferritin (90 ug/L), leukocytes (7.9 x 109/L), and D-dimers (0.40 mg/L). To exclude the presence of other viral infections, serology (Immunoglobulin G [IgG] and Immunoglobulin M [IgM]) against ToRCH (toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus) and parvovirus B19 pathogens were determined. IgG for cytomegalovirus (CMV) and parvoB19 tested positive, whereas IgG and IgM tested negative for the other pathogens. To exclude the presence of other viral infections, serology (IgG and IgM) for ToRCH and parvoB19 was determined. Mother was positive for IgG against CMV and parvoB1, but IgM tested negative for all. Routine RT-PCR was performed for influenza A and B virus, parainfluenza virus type 1–4, human respiratory syncytial virus, rhinovirus, human metapneumovirus, adenovirus, coronavirus, bocavirus, and enterovirus. All PCRs were negative. During admission, maternal vital parameters (temperature, heart frequency, saturation, and blood pressure) remained within normal ranges. After 3 days, the patient was discharged home without complaints.
Table 1.

SARS-CoV-2 PCR Results (Log10 RNA Copies/mL)

April 28April 29April 30May 1May 4 May 5May 8
Maternal
 BloodPOS (4.26)
 UrinePOS (6.70)
 NasopharynxPOS (5.63)POS (4.80)POS (4.96)POS (5.44)
 VaginaPOS (4.58)POS (3.91)
 FecesNEG
 Breastmilk (2×)NEG
Placental
 Maternal sidePOS (4.42)
 Fetal sidePOS (7.15)
Neonate
 Umbilical cord bloodNEG
 BloodNEGNEG
 SputumNEGNEG
 NasopharynxNEGNEGNEG
 UrineNEGNEG
 FecesNEGNEG

Abbreviations: PCR,  polymerase chain reaction; POS, positive PCR; NEG, negative PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Figure 1.

Placental syncytiotrophoblast severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection detected by histochemical staining, specific SARS-CoV-2 RNA probe, and electron microscopy. (A) Gross pathology of the placenta. Case placenta slice is abnormal and shows pale trabeculae in a lattice-like network (1) compared with control, age-matched placenta slice with normal appearance (2). (B) Histopathology of the placenta: diffuse perivillous fibrin and an intervillous inflammatory infiltrate. (1) The intervillous inflammatory cells have a monomorphonuclear, mostly histiocytic appearance by hematoxylin and eosin staining (200×). (2) The macrophages are of the M2 phenotype as shown by CD163+ staining. (C) SARS-CoV-2 infection of the syncytiotrophoblasts; (1) immunohistochemical staining for SARS-CoV-2 spike protein-specific antibody localizing to the cytoplasm (400×) (2) In situ hybridization for SARS-CoV-2 RNA. (D) Electron microscopy of SARS-CoV-2 particle.

SARS-CoV-2 PCR Results (Log10 RNA Copies/mL) Abbreviations: PCR,  polymerase chain reaction; POS, positive PCR; NEG, negative PCR; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Placental syncytiotrophoblast severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection detected by histochemical staining, specific SARS-CoV-2 RNA probe, and electron microscopy. (A) Gross pathology of the placenta. Case placenta slice is abnormal and shows pale trabeculae in a lattice-like network (1) compared with control, age-matched placenta slice with normal appearance (2). (B) Histopathology of the placenta: diffuse perivillous fibrin and an intervillous inflammatory infiltrate. (1) The intervillous inflammatory cells have a monomorphonuclear, mostly histiocytic appearance by hematoxylin and eosin staining (200×). (2) The macrophages are of the M2 phenotype as shown by CD163+ staining. (C) SARS-CoV-2 infection of the syncytiotrophoblasts; (1) immunohistochemical staining for SARS-CoV-2 spike protein-specific antibody localizing to the cytoplasm (400×) (2) In situ hybridization for SARS-CoV-2 RNA. (D) Electron microscopy of SARS-CoV-2 particle.

Placental Examination

Gross examination showed a dense and stiff placenta with pale trabeculae in a lattice-like network (arrows, Figure 1A), in line with the histological results of diffuse perivillous fibrin deposition (Figure 1B-1). There was diffuse damage to the syncytiotrophoblasts associated with an intervillous inflammatory infiltrate, characterized by immunohistochemistry as M2 macrophages (CD163+ [Figure 1B-2] and CD68+ [Supplementary Figure 1]), cytotoxic (CD8), and helper T-cells (CD4) as well as activated B-lymphocytes (PAX5 and CD38) (Supplementary Figure 1). No plasma cells were detected by immunostaining for CD138 (Supplementary Figure 1). There were no signs of villous parenchyma invasion, villitis, or decidual vasculopathy. Immunohistochemical investigation for SARS-CoV-2 antigen expression in combination with SARS-CoV-2 RNA in situ hybridization demonstrated predominant localization of SARS-CoV-2 in the syncytiotrophoblast cells of the placenta (Figure 1C). Electron microscopy confirmed the presence of SARS-CoV-2 particles in the syncytiotrophoblast (Figure 1D), whereas villous and fetal parenchyma showed no evidence of SARS-CoV-2 infection (immunohistochemistry, in situ hybridization, or electron microscopy).

Neonatal Outcome

A female preterm infant was delivered at 31 + 4 weeks of gestation with an Apgar score of 1, 4, and 6 at, respectively, 1, 5, and 10 minutes postpartum, with an umbilical cord blood pH of 6.90, a base excess of −19 mmol/L, and a birth weight of 1880 grams (75th percentile). Neonatal life support was initiated in the absence of spontaneous breathing and an undetectable heart rate. Because of persistent insufficient breathing and a high oxygen demand, the infant was intubated, mechanically ventilated, and admitted to the NICU. During the physical examination, no heart murmur, mucocutaneous signs, rash, or hepatosplenomegaly was noted. Chest radiography showed bilateral opacities consistent with respiratory distress syndrome for which she received repetitive dosages of pulmonary surfactant. Intravenous antibiotics were started on admission and stopped after 36 hours as blood cultures remained negative, and CRP levels were low. Shortly after admission, the infant showed signs of multiple organ failure (elevated creatinine, liver, and cardiac enzymes) and developed a bilateral intraventricular hemorrhage (on the left side a grade 3 and the right side a grade 1). The patient also developed a thrombopenia and leukopenia; however, differentiation showed no lymphopenia. All recovered spontaneously. The high oxygen demand raised the suspicion of persistent pulmonary hypertension of the neonate (PPHN), which was confirmed by echocardiography. Besides the flattened interventricular septum, mild-to-moderate tricuspid regurgitation, a small patent ductus arteriosus with predominantly right-to-left shunt, and a significantly enlarged left main coronary artery (LMCA) were observed (Supplementary Table 1 and Supplementary Figure 2). To treat PPHN and systemic hypotension, inhaled nitric oxide (iNO), inotropic agents, and hydrocortisone were started. Repeated echocardiograms were performed and showed an improvement of the PPHN but increasing diameter (aneurysmatic lesions) of the LMCA (maximum 0.34 mm Z-score + 6.5). Because of the clinical presentation resembling a paediatric multisystem inflammatory syndrome—temporally associated with SARS-CoV-2 (PIMS-TS) [10], immunoglobulins (2 gr/kg) were administered on day 4 and aspirin was started on day 6 to prevent further coronary dilation and thromboembolic complications [11]. At day 14 of life, only mild dilatation of the LMCA was observed. At 4 months postpartum, no signs of coronary artery dilation were observed during echocardiography (Supplementary Table 1). Severely elevated levels of ferritin (14272 ug/L at day 3) as a sign of activated macrophages and significantly elevated D-dimers as a sign of an endotheliitis were seen, both described in fetal inflammatory response syndrome (FIRS) [12]. An active COVID-19 infection was ruled out as all sampling of umbilical cord blood, urine, feces, blood, nasopharynx, and sputum from a deep tracheal aspirate over a period of 9 days tested negative for SARS-CoV-2. Furthermore, the neonate did not develop antibodies to SARS-CoV-2, which were tested in umbilical cord blood, at days 1–3 and week 3 postpartum. The IFN-1 signature was (repetitively) negative. In the course of the first week, inotropic support could be gradually weaned and eventually stopped at day 6 after delivery. In addition, the infant was weaned from iNO and oxygen supplementation followed by detubation at day 6 of life.

Discussion

Our case shows that a maternal SARS-CoV-2 infection during the third trimester of pregnancy is associated with an adverse neonatal outcome based on a placental inflammatory reaction with subsequent dysfunction of the placenta. Remarkable is that the affected mother was in the postinfection period and had no symptoms during the event. The maternal positive IFN-1 signature indicates a strong maternal antiviral response despite the absence of clinical signs of SARS-CoV-2 infection during presentation. We hypothesize that the SARS-CoV-2-associated damage to the placenta early in pregnancy potentially can lead to fetal growth restriction and distress as in our case, while fetal demise may occur when not recognized in time. Although the effects of SARS-CoV-2 infection on pregnancy and neonatal outcomes in the majority of cases seem relatively mild, complications such as miscarriage due to placental infection by SARS-CoV-2 [13], placental abruption [14], (iatrogenic) preterm birth (21.5%), fetal distress (10.1%), and perinatal death [1] have been reported. We diagnosed placental inflammation caused by SARS-CoV-2 infection, based on the detection of virus infection in syncytiotrophoblasts, which was colocalized with syncytiotrophoblast necrosis and a specific B-lymphocyte presentation of histiocytic intervillositis with subsequent placental failure, fetal distress, and perinatal asphyxia. The observed prominent infiltrate with B-lymphocytes has not previously been described in histiocytic intervillositis [15, 16], indicating that it might be one of the histopathological hallmarks that differentiates the histiocytic intervillositis of SARS-CoV-2 infection from chronic histiocytic intervillositis of unknown origin [15, 16]. Our findings are in line with more recent reports of histopathological placental findings in SARS-CoV-2-infected women [3, 17, 18]. Further studies in pregnant women with an active or a COVID-19 infection during pregnancy are warranted to investigate if morphological and histopathological placental characteristics are specific for SARS-CoV-2 infection and if these findings are associated with clinical perinatal outcome. Until now, only a few confirmed cases of vertical transmission of SARS-CoV-2 have been reported [4-8]. In our case, despite the massive placental infection, all neonatal samples were negative for SARS-CoV-2, and we found no evidence for vertical transmission. This is puzzling since angiotensin-converting enzyme 2 receptors seem essential in the transmission and infection by SARS-CoV-2 and are highly expressed on the placental maternal-fetal interface cells [19]. We cannot rule out that the detected SARS-CoV-2 RNA by PCR on the fetal side of the placenta is caused by contamination at the time of sampling, although the number of RNA copies was substantially higher than in maternal blood. During pregnancy, the placenta forms a natural barrier against maternal viral infections although the local immune-tolerant environment might permit viral replication. The specific mechanisms allowing some viruses, such as the rubella virus and the Zika virus, to cause transplacental fetal infection are not well understood [20, 21]. Placental examination of pregnant women infected with the related SARS-CoV of 2002–2003 revealed increased subchorionic and intervillous fibrin with extensive fetal thrombosis [22]. However, in contrast to our case, intervillositis, a histologic characteristic of maternal hematogenous infections that can lead to congenital infection, was not observed in those placentas in 2002–2003 [22]. Unraveling the mechanism by which the placenta prevents the passage of coronaviruses onto the fetus would be of great general interest for better understanding the placental barrier function. Placental SARS-CoV-2 infection can lead to massive local inflammation with the formation of fibrin depositions, thereby decreasing the available maternal-fetal interface necessary for effective gas exchange (Figure 2), which is essential for fetal growth and development. More recent reports have confirmed our immunological findings in the placenta after a COVID-19 infection [3, 17, 18]. We speculate that fetal and subsequent neonatal distress due to placental dysfunction caused by inflammation explain the clinical course resembling a fetal presentation (FIRS) of the pediatric inflammatory multisystem syndrome temporarily associated with SARS-CoV-2 (PIMS-TS) [23]. However, some clinical hallmarks (such as a dilated coronary arteries, extremely high ferritin, and high D-dimer levels) were not consistent with asphyxia alone and suggest a hyperinflammatory response as seen in macrophage activation syndrome [11, 24–26]. In perinatal asphyxia, increased coronary blood flow (myocardial sparing) has been described, but enlargement of coronary arteries has not [27]. Enlargement of coronary arteries is associated with neonatal viral myocarditis, although in combination with severe myocardial dysfunction and left ventricle dilatation [28], and the presence of a coronary arteriovenous fistula, which in our case was ruled out by echocardiography. Vasculitis of the coronary arteries in neonates, and specifically directly postpartum, is extremely rare [29-32]. The observed dilation of the LMCA and left anterior descending artery might be a sign of endotheliitis, which has been described in older children with COVID-19-related disease (PIMS-TS) recently [10]. In these older pediatric patients, high levels of ferritin and D-dimers were described, as seen in our neonate [10]. Also, by the use of pattern recognition receptors [12], the fetal immune system can detect signals produced in the context of structural damage, which can activate a severe immunological response leading to FIRS. This is normally associated with severe bacterial chorioamnionitis [12]. In our case, it might be that placental infection by SARS-CoV-2 resulted in a FIRS-like phenomenon.
Figure 2.

Graphical representation of a healthy placenta compared with perivillous fibrosing and placental inflammation caused by infection of severe acute respiratory syndrome coronavirus 2.

Graphical representation of a healthy placenta compared with perivillous fibrosing and placental inflammation caused by infection of severe acute respiratory syndrome coronavirus 2. In conclusion, we here report a SARS-CoV-2-associated inflammation of the placenta in a mother who was asymptomatic at presentation with severe fetal and neonatal consequences, including coronary artery dilation. This highlights the need for awareness of adverse fetal and neonatal outcomes during the current COVID-19 pandemic, especially considering that the majority of pregnant women appear asymptomatic [33] who are still at risk for developing histopathological placental abnormalities [18]. Click here for additional data file. Click here for additional data file. Click here for additional data file.
  21 in total

Review 1.  Pathological involvement of placenta in COVID-19: a systematic review.

Authors:  Rohini Motwani; Vishwajit Deshmukh; Ashutosh Kumar; Chiman Kumari; Khursheed Raza; Hare Krishna
Journal:  Infez Med       Date:  2022-06-01

2.  Placental pathology in sudden intrauterine death (SIUD) in SARS-CoV-2-positive oligosymptomatic women.

Authors:  Lars-Christian Horn; Irene Krücken; Grit Gesine Ruth Hiller; Maria Niedermair; Kristina Perac; Corinna Pietsch; Anne Kathrin Höhn
Journal:  Arch Gynecol Obstet       Date:  2022-06-18       Impact factor: 2.493

3.  Intrauterine vertical SARS-CoV-2 infection: a case confirming transplacental transmission followed by divergence of the viral genome.

Authors:  M Zaigham; A Holmberg; M L Karlberg; O K Lindsjö; L Jokubkiene; J Sandblom; A S Strand; O Andersson; S R Hansson; D G Nord; P Tannenberg
Journal:  BJOG       Date:  2021-03-22       Impact factor: 7.331

4.  Retrospective observational RT-PCR analyses on 688 babies born to 843 SARS-CoV-2 positive mothers, placental analyses and diagnostic analyses limitations suggest vertical transmission is possible.

Authors:  G Bahadur; M Bhat; S Acharya; D Janga; B Cambell; J Huirne; W Yoong; A Govind; J Pardo; R Homburg
Journal:  Facts Views Vis Obgyn       Date:  2021-03-31

5.  ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection.

Authors:  Smriti Kala; Ksenia Meteleva; Lena Serghides
Journal:  J Infect Dis       Date:  2021-12-08       Impact factor: 5.226

Review 6.  Neonates and COVID-19: state of the art : Neonatal Sepsis series.

Authors:  L Ryan; Frans B Plötz; Agnes van den Hoogen; Jos M Latour; Marina Degtyareva; Maya Keuning; Claus Klingenberg; Irwin K M Reiss; Eric Giannoni; Charles Roehr; Christopher Gale; Eleanor J Molloy
Journal:  Pediatr Res       Date:  2021-12-28       Impact factor: 3.953

7.  Decreased Fetal Movements: A Sign of Placental SARS-CoV-2 Infection with Perinatal Brain Injury.

Authors:  Guillaume Favre; Sara Mazzetti; Carole Gengler; Claire Bertelli; Juliane Schneider; Bernard Laubscher; Romina Capoccia; Fatemeh Pakniyat; Inès Ben Jazia; Béatrice Eggel-Hort; Laurence de Leval; Léo Pomar; Gilbert Greub; David Baud; Eric Giannoni
Journal:  Viruses       Date:  2021-12-15       Impact factor: 5.048

Review 8.  Hematological changes associated with COVID-19 infection.

Authors:  Enass Abdul Kareem Dagher Al-Saadi; Marwa Ali Abdulnabi
Journal:  J Clin Lab Anal       Date:  2021-11-16       Impact factor: 3.124

9.  Evaluation of vertical transmission of SARS-CoV-2 in utero: Nine pregnant women and their newborns.

Authors:  Liang Dong; Shiyao Pei; Qin Ren; Shuxiang Fu; Liang Yu; Hui Chen; Xiang Chen; Mingzhu Yin
Journal:  Placenta       Date:  2021-06-16       Impact factor: 3.481

10.  COVID-19 in pregnancy: Placental and neonatal involvement.

Authors:  Erica Prochaska; Minyoung Jang; Irina Burd
Journal:  Am J Reprod Immunol       Date:  2020-08-15       Impact factor: 3.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.